Overview
NovoCure is a privately held company dedicated to bringing a completely new
cancer treatment modality into clinical use. Professor Yoram Palti,
MD, Ph.D., founded NovoCure in 2000 to develop his research in treating
cancer with electrical fields. The Company builds upon over 8 years
of research including cell culture studies, animal studies, and human trials. In
addition to Professor Palti, the Company has assembled a world class team
of experts who have spent their entire careers inventing, building, or
commercializing innovative medical products.
Team
Yoram Palti, MD, Ph.D., Founder,
Director
Professor Palti is a professor of physiology & biophysics at the Technion – Israel
Institute of Technology. He was formerly an associate professor of
physiology at the University of Maryland School of Medicine. Professor
Palti is an expert in electrophysiology and biomedical engineering. Professor
Palti was previously the head of the Rappaport Institute for Research in
the Medical Sciences, the research arm of the Technion Medical School, for
12 years. He also founded and managed Carmel Biosensor Ltd. and CellSense
Ltd. Professor Palti is the author of more than 30 patents and 70
scientific papers.
Asaf Danziger, CEO
Asaf Danziger joined NovoCure in 2002 with significant experience leading
the development of innovative medical technologies in both corporate management
and hands-on R&D positions. His experience ranges from the definition
and design of advanced devices to monitor critically ill patients, to the
development and introduction of novel therapies in oncology and infectious
diseases. Asaf has particular expertise leading multidisciplinary
teams of engineers, scientists, and physicians from initial concept design
to commercial production. Asaf was previously CEO of Cybro Medical,
the Israeli subsidiary of Imagyn Medical Technologies (Irvine, CA). In
that role, he led product development of cardiac critical care monitoring
systems from concept, to FDA and CE clearance, to subsequent market entry. Earlier
in life, Asaf served as a Communications and Electronics Officer (Captain)
in the Israeli Defense Force, commanding a company of 90 soldiers specializing
in ground radar and advanced electro-optical equipment. Asaf holds
a B.Sc. in material engineering from Ben Gurion University of the Negev,
Israel, where he specialized in microelectronics and biomedicine.
Michael Ambrogi, US General Manager
Mike Ambrogi is the US General Manager for NovoCure. Mike was previously
the General Manager of Deka Research and Development, an intellectual property
company providing product development services to the medical device market. Under
Mike’s direction and the leadership of world-renowned inventor Dean
Kamen, Deka developed several breakthrough products including the Baxter
HomeChoice peritoneal dialysis machine, the Davol Hydroflex surgical irrigation
device, the J&J Cordis Crowne Stent, the J&J Independence Technology
IBOT 3000 mobility system. Mike holds a bachelor’s degree in
mechanical engineering from the Massachusetts Institute of Technology (MIT).
Eilon Kirson, MD, Ph.D., VP of
R & D
Dr. Kirson leads NovoCure’s research and development activities. In
this role, he has had responsibility for NovoCure’s preclinical research,
clinical planning, and interactions with the FDA. Before joining NovoCure,
Dr. Kirson served as Head of Electrophysiology at Carmel Biosensensors. Dr.
Kirson received his B.Med.Sc., MD and Ph.D. in Biophysics from the Hebrew
University and underwent his residency in neurology at Sheba Medical Center,
Tel Ha-Shomer Hospital, Israel.
William F. Doyle, Director
Bill Doyle was a member of Johnson & Johnson’s Medical Devices
and Diagnostics Group Operating Committee and Vice President, Licensing and
Acquisitions. At J&J, Bill was also Chairman of the Medical Devices
Research and Development Council and a director of Johnson & Johnson
Development Corporation, J&J's venture capital subsidiary. Bill
is currently the Managing Director of WFD Ventures LLC, a New York-based
venture capital firm that he founded. WFD Ventures provides equity
financing and industry expertise to medical device companies. Bill
holds a bachelor’s degree in engineering from the Massachusetts Institute
of Technology (MIT) and an MBA from Harvard Business School.
W. Anthony Vernon, Director
Tony Vernon led a number of Johnson & Johnson’s largest and most
successful franchises during a 24 year career at J&J. Tony served
as President of McNeil Consumer Products and Nutritionals, Worldwide President
of The Johnson and Johnson-Merck Joint Venture, President of Centocor, and
Company Group Chairman of DePuy Orthopedics. He also served as
a member of Johnson and Johnson’s Group Operating Committees for Consumer
Healthcare and Nutritionals, Biopharmaceuticals, and Medical Devices and
Diagnostics. Tony holds a bachelor’s degree in history from Lawrence
University and an MBA from Northwestern University's Kellogg School.
CAUTION. Investigational Device. Limited by U.S. law to INVESTIGATION USE ONLY.
Lennart Perlhagen, Director
Lennart Perlhagen is an active investor in emerging healthcare companies
and was the founding investor in NovoCure. Lennart previously founded
Meda AB, a leading specialty pharmaceutical company that grew from a market
capitalization of $10 million to over $4.0 billion during his tenure with
the company. Prior to Meda AB, Lennart was the CEO for Scandinavia
and UK for Pfizer where he gained extensive experience in oncology through
the launch of the chemotherapy agent doxorubicin (Adriamycin). Outside
oncology, Lennart helped lead the commercial launch of omeprazole (Losec/
Prilosec), which became the best selling pharmaceutical product in the
world for AstroZeneca AB where he served as Regional Director for South
Europe.
CAUTION. Investigational Device. Limited by U.S. law to INVESTIGATION USE ONLY.